| Date | Title | Description |
| 03.03.2025 | Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept | Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience
Financing led by Frazier Life Sciences with signif... |
| 13.03.2024 | Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024 | SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:0... |
| 06.03.2024 | Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024 | Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in addit... |
| 23.10.2023 | Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023 | HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials in Australia, targeting multiple solid tumors
The clinical data shows that HMBD-001 is safe and well-tolerated with no d... |
| 19.10.2023 | Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) | Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience's anti-HER3 ADC to be developed for patients with HER3-expressing tumors
Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalti... |
| 21.08.2023 | Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023 | HOUSTON and SINGAPORE, Aug. 21, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcomin... |
| 27.07.2023 | Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development | Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung cancer and patients with genetic aberrations in HER3 signaling
Hummingbird Bioscience has identified gen... |
| 29.05.2023 | Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023 | HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in preclinical models, positioning it as a potentially important new therapy for VISTA-expressing cancers includ... |
| 15.05.2023 | Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma | Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 mAb, in combination with cetuximab, an anti-EGFR mAb, in sqNSCLC
HMBD-001 used as monot... |
| 08.05.2023 | Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases | HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease
Data presented shows preclinical proof of concept for HMBD-011 clearance of V... |
| 15.03.2023 | Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 | Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-targeting programs HMBD-001 (HER3 mAb) and HMBD-501 (HER3 ADC)
HMBD-001 used as monotherapy or in combination with cetuximab effectively inhibits ... |
| 06.03.2023 | Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001 | SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizon... |
| 04.01.2023 | Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program | Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies
Synaffix to receive up to $150m in upfront and milestone payments plus royalties
SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B... |
| 07.11.2022 | Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting | VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies
HMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy a... |
| 01.11.2022 | Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference | SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announ... |
| 23.09.2022 | Hummingbird Bioscience Holds Opening Ceremony for Singapore Science Park Office and Research Facilities | SINGAPORE, Sept. 23, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening ... |
| 19.09.2022 | Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium | SINGAPORE, Sept. 19, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Jerome Boyd-Kirk... |
| 15.09.2022 | ClavystBio launches to translate life sciences breakthroughs into health impact | ClavystBio will invest and work with partners to accelerate life sciences commercialisation in Singapore through three pillars: collaborate, venture and build.
ClavystBio has committed US$220 million to date in investments to launch global ... |
| 08.09.2022 | Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022 | HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors
HMBD-001 has the potential to fully block both ligand-dependent and -independent HER3 signaling
SINGAPORE, Sept. 8, 2022 /PRNewswire/ -... |
| 06.09.2022 | Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference | SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executi... |
| 09.02.2022 | Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers | HOUSTON and SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announce... |
| 06.12.2021 | Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies | HOUSTON and SINGAPORE, Dec. 6, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Res... |
| 29.11.2021 | Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board | HOUSTON and SINGAPORE, Nov. 29, 2021 /PRNewswire/ -- Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disea... |
| 10.11.2021 | Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting | HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation out... |
| 07.10.2021 | Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-driven Cancers | HOUSTON and SINGAPORE, Oct. 7, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinica... |
| 13.09.2021 | Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors | |
| 13.09.2021 | Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors | HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug A... |
| 02.08.2021 | Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers | HOUSTON and SINGAPORE, Aug. 2, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healt... |
| 02.08.2021 | Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers | |
| 12.07.2021 | Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies | HOUSTON and SINGAPORE, July 12, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outc... |
| 12.07.2021 | Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration To Advance Innovative Immunotherapies | |
| 31.05.2021 | Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting | HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development
HMBD-002 is anticipated to enter a Phase 1 clinical trial in 2021
HOUSTON and SINGAPORE, May 31, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clini... |
| 30.05.2021 | Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting | |
| 18.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors
Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 18.05.2021 | Hummingbird Bioscience Raises US$125M in Series C Financing | Hummingbird Bioscience, a Singapore-based clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, closed a US$125m Series C financing round.
The round was led by N... |
| 18.05.2021 | Hummingbird Bioscience : Raises US$125 Million in Series C Financing | Investment round led by Novo Holdings, joined by a syndicate of international biotech investors
Proceeds will support advancement of Hummingbird's lead assets in clinical trials and building of its next-generation portfolio of precision the... |
| 17.05.2021 | Hummingbird Bioscience Raises US$125 Million in Series C Financing | |
| 13.05.2021 | To expand or not to expand? Houston researcher weighs in on global growth | You built your business from the ground up, patiently finding techniques and products that work, carefully crafting solid bonds with your clients. Then one day a new project, opportunity or simple request poses a question: Is it time to bra... |
| 11.05.2021 | Global accelerator announces 5 startups to its Houston cohort | Five Houston companies have been tapped to participate in a Houston-based, early-stage startup accelerator with a national presence.
The accelerator, gBETA, selected the five Houston companies out of over 85 applicants. The cohort represent... |
| 10.05.2021 | Energy giant makes Houston sole headquarters in massive move | Power player NRG Energy is laser focused on Houston. The Bayou City will be the energy giant's new sole headquarters; the company will no longer split between Houston and Princeton, New Jersey.
The move to a single headquarters simplifies b... |
| 05.03.2021 | Photos: Here's a sneak peek at The Ion Houston's construction progress | The Ion Houston is expected to open its doors this year, and the building's exterior is close to completion. Now, the construction team is focusing on interiors and then tenant build outs.
The 270,000-square-foot coworking and innovation hu... |
| 27.01.2021 | Rice University competition to link veterans with NextSeed investors | Rice University's Business Veterans Association has helped military veteran raise more that $3.5 million in investments over the last seven years through it's annual pitch competition. And this year, the stakes are even higher.
The Veterans... |
| 28.12.2020 | Editor's Picks: Top 10 Houston startup feature stories of the year | Editor's note: As 2020 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. This past year, InnovationMap featured profiles on dozens of these Houston startups — from blockchain and software compa... |
| 22.12.2020 | Here are the top 5 Houston startup venture capital deals in 2020 | Editor's note: As 2020 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. When it came to the money raised in Houston, these five startups raised the most, according to reporting done by Innovat... |
| 14.12.2020 | Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers | |
| 16.11.2020 | Houston organization names 10 most promising life sciences startups | Last week, the Rice Alliance for Technology and Entrepreneurship gathered over 1,000 life science experts and attendees virtually for thought leadership as well as 40 company presentations.
The three-day 2020 Virtual Texas Life Science Foru... |
| 04.08.2020 | Houston tech companies have raised over $466M so far this year, new report finds | This year might be a wash for a lot of things, but according to a new fundraising report from Houston Exponential, the Bayou City has seen an increase in funding this year compared to 2019.
The HTX Funding Review found that Houston startups... |
| 26.05.2020 | Houston startup raises $10M, A&M names TMC campus, and more innovation news | Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks. From a Texas university naming its burgeoning new campus to a Houston SaaS startup with fresh funds, here are some short s... |
| 11.05.2020 | Hummingbird Bioscience Raises US$25M in Series B Extension Funding | Hummingbird Bioscience, a Singapore-based innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, closed an extended Series B funding round of US$25m.
The round, which brings the total capi... |
| 11.05.2020 | Biotherapeutics startup Hummingbird Bioscience brings its total Series B funding to $25 million | Hummingbird Bioscience, a startup focused on developing new treatments for cancer and other diseases, announced today it has added $6 million to its previously announced Series B, bringing the round’s total to $25 million.
The extension was... |
| 05.12.2019 | Hummingbird Bioscience secures $19m in Mirae Asset-backed Series B | Premium
Hummingbird Bioscience, focused on precision antibody therapeutics, announced that it has raised $19 million in a Series B funding round co-anchored by Mirae Asset Venture Investment and GNTech Venture Capital.
Continue reading this... |
| 05.12.2019 | Hummingbird Bioscience Raises US$19M in Series B Financing | Hummingbird Bioscience, a Singapore, Houston, Texas and South San Francisco, California-based biotherapeutics company, raised US$19m in Series B financing.
The round was co-led by Mirae Asset Venture Investment and GNTech Venture Capital, w... |
| 17.09.2019 | Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine | → Amgen has enlisted Hummingbird Bioscience on a new antibody discovery pact, turning over some novel targets to see if the smaller player’s “systems biology” platform can yield better therapeutics. Starting with tw... |
